Given the relevance of Hh and TGF-β signaling as drivers of fibrosis and associated cancers, we propose that the effective inhibition of these pathogenic cellular signaling pathways could potentially yield improved efficacy and eventual clinical benefits, compared to the existing therapies, such as pirfenidone and nintedanib. This evidence concerns the gene TGFB1 and cancer.